US 12,220,466 B2
Pharmaceutical formulation
Larry P. Bleier, Vestal, NY (US)
Filed by Cutting Edge Technology, LLC, Endicott, NY (US)
Filed on May 24, 2024, as Appl. No. 18/674,445.
Application 18/674,445 is a continuation of application No. 18/085,810, filed on Dec. 21, 2022, abandoned.
Application 18/085,810 is a continuation in part of application No. 17/707,230, filed on Mar. 29, 2022, granted, now 11,547,637, issued on Jan. 10, 2023.
Application 17/707,230 is a continuation of application No. 16/241,350, filed on Jan. 7, 2019, granted, now 11,311,463, issued on Apr. 26, 2022.
Application 16/241,350 is a continuation of application No. 15/355,185, filed on Nov. 18, 2016, abandoned.
Prior Publication US 2024/0307272 A1, Sep. 19, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 6/58 (2020.01); A61C 3/00 (2006.01); A61C 5/40 (2017.01); A61K 6/15 (2020.01); A61K 6/52 (2020.01); A61K 6/69 (2020.01); A61K 31/327 (2006.01); A61K 31/65 (2006.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01)
CPC A61K 6/69 (2020.01) [A61C 3/00 (2013.01); A61C 5/40 (2017.02); A61K 6/15 (2020.01); A61K 6/52 (2020.01); A61K 6/58 (2020.01); A61K 31/327 (2013.01); A61K 31/65 (2013.01); A61K 9/0063 (2013.01); A61K 9/06 (2013.01)] 16 Claims
OG exemplary drawing
 
1. A method of conditioning a wound including a wound surface, comprising:
chemically debriding the wound by applying a pharmaceutical formulation directly to the wound surface with an instrument including a working edge with a surface roughness of 1 to 50 microns to chemically anesthetize the wound surface; and
mechanically debriding the wound surface by scraping the wound surface with an instrument, the scraping including contacting the wound surface that includes the pharmaceutical formulation directly with the working edge to finish the wound surface to form a wound surface roughness of 1 to 50 microns;
wherein the pharmaceutical formulation comprises:
a tetracycline antimicrobial compound, a salt thereof, a prodrug thereof, in from 25 to 30 weight % of the total weight of the formulation;
at least one peroxide source compound in an effective amount from 1.5 to 44 weight % of the total weight of the formulation; and
at least one gel agent in an effective amount from 1.0 to 90 weight % of the total weight of the formulation.